Cancer reports最新文献

{"title":"Featured Cover","authors":"","doi":"10.1002/cnr2.70265","DOIUrl":"https://doi.org/10.1002/cnr2.70265","url":null,"abstract":"<p>The cover image is based on the article <i>Complete Immunophenotypic Reversal of Chronic Lymphocytic Leukaemia With High Dose Parenteral Methylcobalamin: A Case Report and Brief Review of Cobalamin in Cancer</i> by Carmen Wheatley et al., https://doi.org/10.1002/cnr2.70106.\u0000\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 5","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70265","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144323446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effect of Postoperative Antithrombin Supplementation on the Inflammatory and Coagulation Status of a Surgically Treated Patient With a Malignant Tumor in the Small Pelvis—Case Series","authors":"Ranko Lazović,&nbsp;Ognjenka Šarenac","doi":"10.1002/cnr2.70260","DOIUrl":"https://doi.org/10.1002/cnr2.70260","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Antithrombin has the function of a natural anticoagulant. It is the main component of the inhibitory anticoagulant system, which, under physiological conditions, opposes the procoagulant mechanisms of hemostasis, preventing the occurrence of a hypercoagulable state, the development of thrombosis, and thromboembolic complications. Antithrombin deficiency, acquired or congenital, leads to the development of a hypercoagulable state and thromboembolic complications. Antithrombin also has a significant anti-inflammatory, antimicrobial, and antitumor effect. Patients with malignant diseases are often in a hypercoagulable and proinflammatory state due to the nature of the disease itself and the fact that they undergo extensive surgical procedures and chemotherapy as therapeutic modalities. Therapeutic supplementation with antithrombin products could establish normal coagulability and reduce or suppress the inflammatory response. However, previous randomized studies have not shown a long-term benefit of this approach.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case</h3>\u0000 \u0000 <p>In our female patients who underwent multiple organ resections, with advanced colorectal cancer and acute pancreatitis treated surgically, with a pronounced inflammatory and hypercoagulable response on the first postoperative day, antithrombin supplementation in the first four postoperative days contributed to the establishment of normal coagulability confirmed by the ROTEM analysis while suppressing the inflammatory response followed by inflammatory laboratory parameters.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Compensating for the antithrombin deficit in the first four postoperative days may benefit the specified patient group, with careful monitoring of hemostatic and inflammatory parameters.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 6","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70260","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144315142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Facilitating Advance Care Planning Conversations Among Patients With Cancer and Their Care Partners Utilizing a Conversation Game: A Pilot Study","authors":"Kylee Kimbel,&nbsp;Michael Hayes,&nbsp;Morgan Bucher,&nbsp;William A. Calo,&nbsp;Tullika Garg,&nbsp;Monika Joshi,&nbsp;Hannah Kuntz,&nbsp;Terrence E. Murphy,&nbsp;Erika VanDyke,&nbsp;Emily Wasserman,&nbsp;Lauren J. Van Scoy","doi":"10.1002/cnr2.70250","DOIUrl":"https://doi.org/10.1002/cnr2.70250","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Patients with cancer should engage in decision-making throughout the course of their illness and treatment. Current guidelines recommend early, frequent advance care planning (ACP) conversations among clinicians, patients, and care partners (CPs) and advance directive (AD) completion. However, only 55% of patients with cancer have completed such directives, suggesting the need for interventions to increase rates of ACP. The <i>Hello</i> game has been shown to be effective in promoting ACP in several populations but has not been tested in patients with cancer or their CP.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>To assess the acceptability of <i>Hello</i> and determine the modifications necessary for use in cancer populations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>This convergent mixed methods study involved seven dyads (7 patients with cancer and their 7 CPs to total <i>n</i> = 14); dyads played <i>Hello</i> in groups of 2–4. Post-game, dyads completed satisfaction and acceptability questionnaires and focus groups. Qualitative thematic analysis was performed; quantitative data was summarized.</p>\u0000 \u0000 <p>Patients' mean age was 56.4 years—43% were female, 57% had genitourinary cancer, and 43% had breast cancer. Three themes emerged from both patient and CP focus groups (<i>n</i> = 14 individuals): (1) Participants enjoyed the group dynamics and relating to peers when playing <i>Hello</i>; (2) <i>Hello</i> serves as a helpful conversation starter; (3) modifications could help tailor <i>Hello</i> for use in cancer context—particularly adding more questions about quality of life and mental health. The patient focus groups had an additional theme: (4) Patients with localized cancer may have a different experience with <i>Hello</i> when compared to those with advanced cancer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p><i>Hello</i> was well-received by dyads, and their feedback was used to tailor <i>Hello</i> for patients with cancer and their CPs. Next steps for this project include assessing the acceptability of the modified game.</p>\u0000 \u0000 <p><b>Trial Registration:</b> clinicaltrials.gov: NCT06028152</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 6","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70250","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144308685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Prognosis Prediction Model for Endometrial Cancer Based on DNA Methylation Signature","authors":"Ran Ran,&nbsp;Ming Wang,&nbsp;Jinwei Miao","doi":"10.1002/cnr2.70218","DOIUrl":"https://doi.org/10.1002/cnr2.70218","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>DNA methylation alteration is a common event during the carcinogenesis and progression of endometrial cancer (EC). Our study aimed to investigate the value of DNA methylation-related genes in predicting the prognosis and immunotherapy response for EC patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The clinical information and the expression of DNA methylation-related genes of 544 endometrial cancers were obtained from the Cancer Genome Atlas (TCGA) database. The univariate Cox regression analysis and the LASSO regression analysis were subsequently used to identify prognosis-related methylation regulators and construct a risk model. Gene functional enrichment analysis, immune infiltration analysis, drug sensitivity analysis, and molecular feature analysis were performed in different subgroups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>25 methylation-Related gene signatures were found in EC patients and are correlated to tumor differentiation and tumor metastasis. By LASSO-Cox regression analyses, a recurrence prediction model and a prognostic-related model were constructed based on methylation-related genes in the TCGA training cohort. The Area Under the Curve (AUC) values of the recurrence prediction model were 0.671, 0.708, and 0.689 for 1-, 3-, and 5-year time points, respectively, while those of the prognostic model were 0.731, 0.717, and 0.725. The relationship of risk score (RS) with ER/PR-related genes, immune checkpoint expressions, and IC50s of paclitaxel, cisplatin, tamoxifen, and cetuximab was investigated. The results showed That patients in the low-risk group are more effective in cetuximab and immune checkpoint blockade (ICB) treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The model based on the methylation-related genes showed promising outcomes in predicting the recurrence and treatment response of EC. The patients with high-risk scores showed a poorer prognosis and may benefit more from the treatment of cetuximab or immune checkpoint inhibitors.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 6","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70218","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144308684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Clinical Outcomes of Preoperative Self-Expandable Metal Stent Placement as Bridge to Surgery for Obstructive Colorectal Cancer","authors":"Ryosuke Aoki,&nbsp;Nao Hondo,&nbsp;Masato Kitazawa,&nbsp;Satoshi Nakamura,&nbsp;Makoto Koyama,&nbsp;Masahiro Kataoka,&nbsp;Hirokazu Tanaka,&nbsp;Takuya Iguchi,&nbsp;Yonghan Park,&nbsp;Yuji Soejima","doi":"10.1002/cnr2.70255","DOIUrl":"https://doi.org/10.1002/cnr2.70255","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Self-expandable metal stent (SEMS) placement for obstructive colorectal cancer (OCRC) is widely performed as a bridge to surgery because of its lower mortality rate than emergency surgery. However, the long-term outcomes remain unclear because of the risk of complications and cancer recurrence. This study investigated the short- and long-term outcomes of SEMS placement for OCRC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>We retrospectively reviewed the clinicopathological data of patients with OCRC who underwent preoperative treatment and tumor resection at our institution between April 2004 and March 2022. Among 113 patients with OCRC, 30 underwent SEMS placement (Group S) and 36 underwent ileus tube insertion (Group T); Group S had more older patients and fewer pT4 cases; no other characteristics differed. Incidence of severe complications was 0% versus 16.7% (<i>p</i> &lt; 0.01); postoperative hospital stay was 14.3 versus 26.6 days (<i>p</i> &lt; 0.01); medical costs were comparable between the groups. The long-term outcomes of Group S and patients with non-OCRC who underwent surgery during the same period were compared after propensity score matching. The 5-year survival rates were 69.5% and 77.1%; the 5-year recurrence-free survival rates were 44.5% and 55.5%, without significant difference.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In conclusion, SEMS placement was more effective than ileus tube placement in treating OCRC.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 6","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70255","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144299902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stereotactic Body Radiation Therapy for Oligometastatic Recurrent Esophageal Squamous Cell Carcinoma: A Retrospective Cohort Study From a Single Tertiary Center","authors":"Atsuto Katano,&nbsp;Masanari Minamitani,&nbsp;Shingo Ohira,&nbsp;Subaru Sawayanagi,&nbsp;Hideomi Yamashita","doi":"10.1002/cnr2.70248","DOIUrl":"https://doi.org/10.1002/cnr2.70248","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Oligometastatic disease, characterized by a limited number of metastatic lesions, has gained significant attention for its potential to enable long-term survival with definitive local therapies. Esophageal cancer, an aggressive malignancy often diagnosed at advanced stages, carries a poor prognosis, particularly in cases involving distant metastasis. Stereotactic body radiation therapy (SBRT) has emerged as a promising local treatment modality for oligometastatic disease, offering precise high-dose radiation delivery. This study evaluated the outcomes of SBRT in patients with oligometastatic esophageal cancer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This retrospective study analyzed 33 patients with esophageal cancer who underwent SBRT for all oligometastatic lesions at a single institution between August 2014 and March 2024. The inclusion criteria were patients with squamous cell carcinoma, extracranial oligometastases, and no concurrent systemic therapy. Oligometastatic diseases were categorized into de novo, repeat, and induced subtypes. Survival outcomes, including overall survival (OS) and progression-free survival (PFS), were assessed using the Kaplan–Meier method.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The study cohort included 33 patients with a median age of 68 years. Most patients had one treated lesion, with SBRT doses ranging from 25–50 Gy in 4–10 fractions. Median OS and PFS were 17.3 months and 4.2 months, respectively. Patients with locoregional recurrence exhibited longer median PFS (5.1 months) and OS (19.6 months) compared to those with distant metastases (PFS: 3.0 months; OS: 14.8 months). Stratification by oligometastatic subtype revealed the best outcomes in de novo cases, with a median OS of 19.6 months and PFS of 8.8 months. Local control at 1 year was 90.7% for the entire cohort, with limited severe late adverse events.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>SBRT demonstrated promising outcomes in patients with oligometastatic esophageal cancer, offering high local control with minimal toxicity. Although these results highlight the feasibility of SBRT, larger prospective studies are needed to validate these findings.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 6","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70248","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144299762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unveiling the Burden of Leukemia in Eritrea (2010–2020): Chronic Leukemia Stability, Rising ALL Incidence, and the Enigma of CML in a Low-Resource Setting","authors":"Daniel Mebrahtu Abraha,&nbsp;Samuel Tekle Mengistu,&nbsp;Efriem Ghirmay,&nbsp;Eden Gebresilassie,&nbsp;Ghirmay Embaye Zerat,&nbsp;Rahwa Kokob,&nbsp;Asmeret Tesfazghi,&nbsp;Solomon Negash,&nbsp;Tsega Daniel,&nbsp;Salih Mohammed,&nbsp;Oliver Okoth Achila","doi":"10.1002/cnr2.70203","DOIUrl":"https://doi.org/10.1002/cnr2.70203","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Little research has been conducted on the epidemiology of leukemia in Eritrea. In this retrospective study, we evaluated the burden and trends of acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), and overall leukemia in Eritrea.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>An audit of leukemia cases recorded in laboratory logbooks at the National Health Laboratory and Orotta Referral and Teaching Hospital between January 2010 and December 2020 was performed. In addition to leukemia subtypes, variables such as age, sex, and year of incidence were retrieved. Relevant estimates assessed included crude incidence rates (CIR), age-standardized rates (ASIR), and estimated annual percentage change (EAPC). In total, 372 confirmed cases of leukemia were recorded between 2010 and 2020. The median (interquartile range [IQR]) age, maximum–minimum age, and male-to-female ratio were as follows: 48 years (24.5–60 years), 2–91 years, and 210:161 (1.3:1), respectively. The estimated all-age CIR and ASIR over the study period were 9.22 per 100,000 and 30.1 per 100,000, respectively. Analysis of cumulative (2010–2020) CIR per 100,000 (ASIR per 100 000) for ALL, AML, CLL, and CML were as follows: 2.01 (3.87); 0.94 (2.38); 2.94 (15.37); and 3.61 (24.03). Additionally, the median (IQR) age differed significantly across leukemia subtypes: ALL (23.0 years, IQR: 10.0–39.0); AML (30 years, IQR: 20–56 years); CLL (59.0 years, IQR: 40.75–66.75 years); and CML (49 years, IQR: 39.25–60 years), <i>p</i> value (Kruskal–Wallis) &lt; 0.05. The proportion of leukemia types did not differ significantly between males and females. Unlike other leukemia subtypes, the evaluation of ALL's EAPC demonstrated that the incidence of leukemia increased over time, 21.9 (95% CI: 3.1–44.1), <i>p</i> value = 0.025.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The burden of leukemia in Eritrea remained relatively stable. However, due to underreporting and underdiagnosis, we believe the true burden of leukemia is likely higher. Furthermore, an upward trend in the burden of ALL was observed. Lastly, expanding diagnostic services to other sub-zones, establishing a national cancer registry, and prioritizing research remain critical in Eritrea.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 6","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70203","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144299903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between Maternal Diet During Pregnancy and the Risk of Childhood Acute Lymphoblastic Leukemia. An Overview","authors":"Kathya Torres-Duarte,&nbsp;Laura Marcela Chávez Rodríguez,&nbsp;Catalina Mora-Becerra,&nbsp;Jaime Moreno-Chaparro,&nbsp;Hernando Gaitán-Duarte","doi":"10.1002/cnr2.70231","DOIUrl":"https://doi.org/10.1002/cnr2.70231","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The effect of maternal habits during pregnancy has been studied to determine their association with the risk of childhood acute lymphoblastic leukemia (ALL).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>To synthesize current evidence on the association between maternal diet during pregnancy and the risk of childhood ALL.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Overview of Systematic reviews (SRs) published until September 2023 were searched in MEDLINE (Pubmed), EMBASE, SCOPUS, Web of Science, and LILACS databases. Effect estimates and meta-aggregate analysis results are presented according to maternal exposure subgroups: (I) alcohol; (II) animal protein; (III) coffee; (IV) fruits and vegetables consumption; and (V) folic acid supplementation. The risk of bias was assessed independently by two authors using the AMSTAR II tool. PROSPERO protocol CRD42023462391.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Thirteen SRs were included; of these, according to the AMSTAR II tool, three were graded as high-quality, three as moderate-quality, five as low-quality, and two as critically low-quality reviews. The inclusion of meat (fish), fruits, and vegetables in the diet during pregnancy, as well as folic acid supplementation, seems to have a protective effect against the development of childhood ALL. In contrast, the daily frequency and amount of coffee consumption during pregnancy could influence the development of this type of cancer in the pediatric population. We did not find enough evidence supporting the association of alcohol as a risk factor of childhood ALL.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The low certainty of the evidence found makes it impossible to establish clear associations between maternal exposure during pregnancy to any of the five nutritional factors here evaluated and the development of childhood ALL.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 6","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70231","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144255921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinicopathological Factors Predisposing to No. 12a Lymph Node Metastasis in Gastric Cancer: A Prospective Cohort Analysis","authors":"Amirmohsen Jalaeefar,&nbsp;Habibollah Mahmoodzadeh,&nbsp;Mohammad Shirkhoda,&nbsp;Ramesh Omranipour,&nbsp;Seyed Rouhollah Miri,&nbsp;Narjes Mohammadzadeh,&nbsp;Arshia Zardoui,&nbsp;Amirsina Sharifi","doi":"10.1002/cnr2.70239","DOIUrl":"https://doi.org/10.1002/cnr2.70239","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The current standard surgical procedure for gastric cancer (GC) is gastrectomy and D2 lymphadenectomy, which includes harvesting No. 12a lymph node (LN) station.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>The purpose of this study was to identify the clinicopathologic factors associated with No. 12a lymph node metastasis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>Eighty-nine patients with GC undergoing gastrectomy and D2 lymphadenectomy were included in this single-arm prospective cohort study. Logistic regression analyses were used to clarify the correlation between No. 12a involvement and clinicopathologic characteristics. Eighty-nine patients (66% males) with a mean age of 58.86 ± 13.06 years were included. The upper third of the stomach was the most common tumor site (43.8%). neoadjuvant chemotherapy (NAC) was administered to 77 patients (86.5%). Total gastrectomy was the most common surgical procedure (67.4%), and 49.4% of tumors were poorly differentiated. Ten patients (11.24%) had 12a LN metastasis. Patients with 12a LN involvement exhibited greater number of harvested LNs in other stations (28.5[27–39.25] vs. 25[21–30], <i>p =</i> 0.024) and a higher presence of LN involvement in other stations (22[11–32] vs. 0[0–4], <i>p</i> = &lt; 0.001). Univariate logistic regression analysis showed that the number of harvested other nodes (OR: 1.11[1.02–1.21]), number of involved other nodes (1.23[1.11–1.37]), omental involvement (OR: 10.86[1.84–64.24.57]), lymphovascular invasion (6.90[1.37–34.70]), and perineuronal invasion (OR: 6.16[1.23–31.11]) were significantly associated with No. 12a station metastasis. However, in multivariate logistic regression, only the number of involved other nodes showed a significant association with No. 12a station metastasis (OR: 1.30[1.09–1.55]). There was no difference between patients who received NAC and who did not in terms of No. 12a involvement (<i>p</i> value = 0.61).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Among clinicopathologic risk factors, involvement of other lymph node stations was significantly associated with No. 12a lymph node metastasis. Therefore, No. 12a lymph node dissection should be considered in patients with advanced gastric cancer.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 6","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70239","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144264643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Imatinib Desensitization After a Type IV Hypersensitivity Reaction in a Gastrointestinal Stromal Tumor Patient—A Case Report","authors":"Maud B. A. van der Kleij,&nbsp;Tristan V. M. Bruijn,&nbsp;Raween W. Kalicharan,&nbsp;Yannick S. Elshot,&nbsp;Maxime C. F. Pilon,&nbsp;Mark Oostdijk,&nbsp;Matthijs M. Tibben,&nbsp;Bastiaan Nuijen,&nbsp;Alwin D. R. Huitema,&nbsp;Thomas Rustemeyer,&nbsp;Neeltje Steeghs","doi":"10.1002/cnr2.70238","DOIUrl":"https://doi.org/10.1002/cnr2.70238","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Imatinib treatment is approved for several indications, including chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). Although adverse events are common, hypersensitivity reactions are not. Because there is a clear clinical benefit of imatinib treatment, re-introduction of imatinib after a hypersensitivity reaction should be considered.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case</h3>\u0000 \u0000 <p>Here we present a case report of a 68-year-old patient with a GIST diagnosis who was re-introduced to imatinib after a type IV hypersensitivity reaction via desensitization. A desensitization plan, a plan for formulation of low-dose imatinib capsules, and the essential steps when considering desensitization are discussed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our case of a patient with a type IV hypersensitivity reaction after starting imatinib treatment demonstrates that desensitization is a feasible option after serious cutaneous adverse events in specific cases, when done with good interdisciplinary collaboration and clinical management.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 6","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70238","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144264644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}